JP2008511608A - 髄膜炎菌外膜ベシクルに関する改良 - Google Patents

髄膜炎菌外膜ベシクルに関する改良 Download PDF

Info

Publication number
JP2008511608A
JP2008511608A JP2007529033A JP2007529033A JP2008511608A JP 2008511608 A JP2008511608 A JP 2008511608A JP 2007529033 A JP2007529033 A JP 2007529033A JP 2007529033 A JP2007529033 A JP 2007529033A JP 2008511608 A JP2008511608 A JP 2008511608A
Authority
JP
Japan
Prior art keywords
omv
composition
meningococcal
serum
subtype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007529033A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008511608A5 (cg-RX-API-DMAC7.html
Inventor
フィリップ オステル,
リノ ラプッオリ,
マリアグラツィア ピッツァ,
Original Assignee
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル filed Critical ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル
Publication of JP2008511608A publication Critical patent/JP2008511608A/ja
Publication of JP2008511608A5 publication Critical patent/JP2008511608A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2007529033A 2004-09-03 2005-09-05 髄膜炎菌外膜ベシクルに関する改良 Pending JP2008511608A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0419627.5A GB0419627D0 (en) 2004-09-03 2004-09-03 Immunogenic bacterial vesicles with outer membrane proteins
PCT/IB2005/002801 WO2006024946A2 (en) 2004-09-03 2005-09-05 Improvements relating to meningococcal outer membrane vesicles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011185225A Division JP2011236254A (ja) 2004-09-03 2011-08-26 髄膜炎菌外膜ベシクルに関する改良

Publications (2)

Publication Number Publication Date
JP2008511608A true JP2008511608A (ja) 2008-04-17
JP2008511608A5 JP2008511608A5 (cg-RX-API-DMAC7.html) 2011-10-13

Family

ID=33156002

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007529033A Pending JP2008511608A (ja) 2004-09-03 2005-09-05 髄膜炎菌外膜ベシクルに関する改良
JP2011185225A Pending JP2011236254A (ja) 2004-09-03 2011-08-26 髄膜炎菌外膜ベシクルに関する改良

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011185225A Pending JP2011236254A (ja) 2004-09-03 2011-08-26 髄膜炎菌外膜ベシクルに関する改良

Country Status (13)

Country Link
US (1) US8808711B2 (cg-RX-API-DMAC7.html)
EP (1) EP1784213B1 (cg-RX-API-DMAC7.html)
JP (2) JP2008511608A (cg-RX-API-DMAC7.html)
CN (2) CN101115501A (cg-RX-API-DMAC7.html)
AU (1) AU2005278896B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0514883A (cg-RX-API-DMAC7.html)
CA (1) CA2578588A1 (cg-RX-API-DMAC7.html)
ES (1) ES2527859T3 (cg-RX-API-DMAC7.html)
GB (1) GB0419627D0 (cg-RX-API-DMAC7.html)
MX (1) MX2007002633A (cg-RX-API-DMAC7.html)
NZ (1) NZ553521A (cg-RX-API-DMAC7.html)
RU (1) RU2420312C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006024946A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
EP1179072A2 (en) 1999-05-19 2002-02-13 Chiron S.P.A. Combination neisserial compositions
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
NZ572054A (en) 2006-03-22 2011-12-22 Novartis Ag Regimens for immunisation with meningococcal conjugates
HRP20120433T1 (en) 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
SI2268618T1 (sl) 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
MX2010012999A (es) * 2008-05-30 2012-03-07 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
GB0822634D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
JP5814933B2 (ja) 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
US9808517B2 (en) 2012-04-06 2017-11-07 Cornell University Subunit vaccine delivery platform for robust humoral and cellular immune responses
ES2847923T3 (es) 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
BR112015018877A2 (pt) 2013-02-07 2017-08-22 Externautics Spa Método para preparar uma composição farmacêutica, e, composição farmacêutica imunogênica
CN106661092B (zh) 2014-02-28 2021-07-06 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
AU2015289193A1 (en) * 2014-07-17 2017-02-02 Glaxosmithkline Biologicals S.A. Meningococcus vaccines
MX2017000776A (es) 2014-07-17 2017-05-04 Glaxosmithkline Biologicals Sa Polipeptidos fhbp meningococicos modificados.
KR101742236B1 (ko) * 2014-10-29 2017-05-31 인하대학교 산학협력단 쯔쯔가무시병에 대한 면역 조성물 및 이의 제조방법
CN105669964B (zh) * 2016-03-04 2017-11-21 博瑞生物医药(苏州)股份有限公司 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
AU2018330322A1 (en) 2017-09-08 2020-03-19 Evelo Biosciences, Inc. Bacterial extracellular vesicles
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105890A2 (en) * 2002-06-13 2003-12-24 Glaxosmithkline Biologicals S.A. Vaccine composition
WO2004019977A2 (en) * 2002-08-30 2004-03-11 Chiron Srl Improved bacterial outer membrane vesicles
JP2004512269A (ja) * 2000-07-27 2004-04-22 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のためのワクチン
WO2004054611A1 (en) * 2002-12-16 2004-07-01 Nasjonalt Folkehelseinstitutt Meningococcal vaccine based on outer membrane proteins porb2 and pora

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
DK0624376T3 (da) 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
DK0710118T3 (da) 1994-04-20 1999-08-09 Us Army Vaccine mod infektioner med gram-negative bakterier
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
JP2001510169A (ja) 1997-07-17 2001-07-31 ノース アメリカン ワクチン, インコーポレイテッド B型髄膜炎菌性ポーリンおよびH.influenzae多糖体を含む免疫原性結合体
EP1741443B1 (en) 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
CN100350972C (zh) * 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
CN1674933B (zh) 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
US7031284B2 (en) * 2003-03-03 2006-04-18 Interdigital Technology Corporation Wireless communication method and apparatus for optimizing multi-user detection
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7628995B2 (en) 2003-12-23 2009-12-08 Glaxosmithkline Biologicals S.A. Outer membrane vesicles and uses thereof
ES2337309T5 (es) * 2006-06-12 2013-07-30 Glaxosmithkline Biologicals S.A. Vacuna

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004512269A (ja) * 2000-07-27 2004-04-22 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のためのワクチン
WO2003105890A2 (en) * 2002-06-13 2003-12-24 Glaxosmithkline Biologicals S.A. Vaccine composition
WO2004019977A2 (en) * 2002-08-30 2004-03-11 Chiron Srl Improved bacterial outer membrane vesicles
WO2004054611A1 (en) * 2002-12-16 2004-07-01 Nasjonalt Folkehelseinstitutt Meningococcal vaccine based on outer membrane proteins porb2 and pora

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6011030459; New Zealand Medical Journal Vol.117,No.1200, 200408 *
JPN6011030462; Vaccine Vol.22,No.17-18, 200406, p2171-2180 *
JPN6011030464; FEMS Immunology and Medical Microbiology Vol.41,No.3, 200407, p205-210 *
JPN6011030465; Vaccine Vol.22,No.23-24, 200408, p3008-3013 *
JPN6014023666; Vaccine Vol.14,No.10, 1996, pp.1009-1015
JPN6014023876; Infection and Immunity , 2003, p.6367-6371

Also Published As

Publication number Publication date
RU2420312C2 (ru) 2011-06-10
WO2006024946A2 (en) 2006-03-09
AU2005278896B2 (en) 2011-12-22
NZ553521A (en) 2010-01-29
RU2007111838A (ru) 2008-10-10
CN101115501A (zh) 2008-01-30
US20080063665A1 (en) 2008-03-13
JP2011236254A (ja) 2011-11-24
BRPI0514883A (pt) 2008-06-24
CA2578588A1 (en) 2006-03-09
EP1784213A2 (en) 2007-05-16
GB0419627D0 (en) 2004-10-06
US8808711B2 (en) 2014-08-19
MX2007002633A (es) 2007-05-15
WO2006024946A3 (en) 2006-11-30
EP1784213B1 (en) 2014-10-29
ES2527859T3 (es) 2015-01-30
CN101862451A (zh) 2010-10-20
AU2005278896A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
JP2011236254A (ja) 髄膜炎菌外膜ベシクルに関する改良
RU2475496C2 (ru) МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
JP6077983B2 (ja) 外膜タンパク質を有する免疫原性細菌小胞
JP5701058B2 (ja) 髄膜炎菌ワクチン処方物
US20130071422A1 (en) Adjuvanted vaccines for serogroup b meningococcus
JP2015110653A (ja) 髄膜炎菌fHBP配列を含むハイブリッドポリペプチド
JP2012512240A (ja) ヘモグロビン受容体を含む髄膜炎菌ワクチン
KR102963606B1 (ko) 면역원성 조성물
JP2012502013A (ja) 外膜小胞初回刺激−タンパク質追加免疫ワクチン
EA048463B1 (ru) Иммуногенные композиции
AU2013202593A1 (en) Adjuvanted vaccines for serogroup B meningococcus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110613

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110826

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120720

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120813

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140116